Skip to main content
. Author manuscript; available in PMC: 2022 Feb 28.
Published in final edited form as: Nature. 2021 Apr 14;592(7856):799–803. doi: 10.1038/s41586-021-03422-5

Extended Data Fig. 9 |. AMBRA1 deficiency is synthetic lethal with CHK1 inhibitors in vivo.

Extended Data Fig. 9 |

a, Cell viability of Ambra1+/+ and Ambra1gt/gt MEFs treated with AZD7762 or vehicle for 24 h (n = 4 independent experiments). P values by two-tailed unpaired t-test. b, Box plots (centre line, median; box limits, 25th and 75th percentile; whiskers, minimum and maximum) indicating weight of Ambra1+/+ and Ambra1gt/gt MEF xenografts referred to in Fig. 3f (Ambra1+/+ + vehicle, n = 8; Ambra1+/+ + AZD7762, n = 8; Ambra1gt/gt + vehicle, n = 10; Ambra1gt/gt + AZD7762, n = 11 mice). P values by two-tailed unpaired t-test. c, Cell death percentage in control U87-MG cells or overexpressing cyclin D1, either untreated or treated with AZD7762 for 24 h; mean ± s.e.m. (n = 3 independent experiments). P values by two-sided one-way ANOVA followed by Tukey’s multiple comparisons test. Unless otherwise stated, data are mean ± s.d.